Key Highlights
- ARK Invest executed just three stock purchases last week: Figma, Arcturus Therapeutics, and 10x Genomics
- The firm acquired 337,381 Figma shares valued at more than $8.1 million on March 20
- ARK divested 45,998 Circle Internet Group shares worth approximately $5.9 million through ARKK and ARKW funds
- Despite 40% quarterly revenue expansion, Figma shares remain 83% below 2025 peak values
- Additional sales included Teradyne, Bullish, Guardant Health, and Butterfly Network holdings
Cathie Wood’s ARK Invest demonstrated unusual restraint last week, executing only three stock acquisitions during a period when major indices declined for the fourth consecutive week. The prominent investment firm’s founder and chief executive made notably fewer trades than typical.
Wood generally increases buying activity when markets experience downturns, making this limited trading pattern particularly noteworthy for market observers tracking the firm’s movements.
The three companies receiving fresh capital allocations were Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, ARK reduced exposure to multiple holdings, most notably Circle Internet Group, a cryptocurrency-linked enterprise.
Figma operates as a collaborative cloud platform enabling design work for digital applications, websites, and online products. ARK acquired 337,381 Figma shares on March 20 through its ARKK and ARKW exchange-traded funds, representing an investment of $8,171,367.
Shares have plummeted 83% from their summer 2024 highs, following a rally that had pushed the stock above four times its $33 initial public offering price. Nevertheless, Figma delivered 40% revenue expansion in its latest quarterly report, accelerating from 38% in the prior period.
The company’s net dollar-retention metric reached 136%, indicating that current clients increased spending by 36% year-over-year. This represents the highest figure for this performance indicator in a two-year span.
Wall Street analysts project revenue growth will moderate to 30% in the current year and 20% in the following year. Figma’s lack of substantial profitability has created headwinds for the stock price.
Cryptocurrency Exposure Trimmed Through Circle Internet Sale
Regarding digital assets, ARK liquidated 45,998 shares of Circle Internet Group through ARKK and ARKW, generating proceeds of $5,902,923. The investment firm had been systematically reducing this position throughout the trading week.
Circle Internet operates as a cryptocurrency-affiliated enterprise, primarily recognized for its involvement in the USD Coin stablecoin infrastructure.
ARK simultaneously disposed of 19,206 Teradyne shares for $5,807,894, together with 103,379 Bullish shares worth $4,093,808 and 9,621 Guardant Health shares generating $857,038. The firm also sold 182,353 Butterfly Network shares for $723,941.
Biotechnology Selections: Arcturus and 10x Genomics
Arcturus Therapeutics develops therapeutic interventions for uncommon respiratory and hepatic conditions using messenger RNA platforms. ARK purchased Arcturus shares during three separate trading sessions last week, with the most recent acquisition of 22,773 shares on Friday totaling $153,034 via its ARKG ETF.
Arcturus has experienced declining revenue for three consecutive years, with projections indicating further contraction through 2026. Despite this challenge, management recently announced extended financial resources lasting through at least Q2 2028.
10x Genomics manufactures research instrumentation for life sciences applications, featuring its Chromium system for analyzing individual cell genetics. ARK accumulated 192,658 shares throughout the week across ARKK and ARKG funds, investing $3,541,054.
The enterprise debuted publicly at $38 per share and currently trades near half that valuation. It has yet to achieve profitability, and management’s 2026 outlook indicates potential revenue contraction when accounting for licensing revenues from prior patent settlements.
